-
Mashup Score: 1Beating the mighty Demodex mites - 2 year(s) ago
Demodex blepharitis is a virtual epidemic in the US; an estimated 20 million people have blepharitis, and of that population, almost half have Demodex. A new therapeutic is the sole treatment option that targets the disease.
Source: Ophthalmology TimesCategories: Latest Headlines, OphthalmologyTweet
-
Mashup Score: 2Beating the mighty Demodex mites - 2 year(s) ago
Demodex blepharitis is a virtual epidemic in the US; an estimated 20 million people have blepharitis, and of that population, almost half have Demodex. A new therapeutic is the sole treatment option that targets the disease.
Source: Ophthalmology TimesCategories: Latest Headlines, OphthalmologyTweet-
An estimated 20 million people in the US have #blepharitis, and of that population, almost half have #Demodex. A new #therapeutic is the sole treatment option that targets the disease. Learn more: https://t.co/4Ez7YZJ0DU #Ophthalmology #clinical #ocular #cataract https://t.co/UC3xDaUuJ4
-
-
Mashup Score: 2Beating the mighty Demodex mites - 2 year(s) ago
Demodex blepharitis is a virtual epidemic in the US; an estimated 20 million people have blepharitis, and of that population, almost half have Demodex. A new therapeutic is the sole treatment option that targets the disease.
Source: Ophthalmology TimesCategories: Latest Headlines, OphthalmologyTweet-
An estimated 20 million people in the US have #blepharitis, and of that population, almost half have #Demodex. A new #therapeutic is the sole treatment option that targets the disease. Learn more: https://t.co/MtFEgrvV7R #Ophthalmology #clinical #ocular #cataract https://t.co/C5um1llOFh
-
-
Mashup Score: 3Tarsus announces positive topline data of TP-03 from Saturn-2 Phase 3 trial, expects to file NDA later this year - 2 year(s) ago
TP-03 met the primary and all secondary endpoints, effectively resolved Demodex blepharitis and was well-tolerated with no serious treatment-related adverse events. 56% of patients on TP-03 achieved the primary endpoint of complete collarette cure.
Source: Ophthalmology TimesCategories: Latest Headlines, OphthalmologyTweet-
NEWS: @TarsusRx today announced positive topline data of TP-03 from Saturn-2 Phase 3 trial, expects to file NDA later this year More: https://t.co/qUvHATLMio #Ophthalmology #Demodex #blepharitis #clinicaltrials #clinical https://t.co/ZnMz0Cgemk
-
-
Mashup Score: 1
In this Healio Video Perspective, Bobak Azamian, MD, PhD, CEO and co-founder of Tarsus Pharmaceuticals, discusses topline data from the Saturn-2 phase 3 study of TP-03 for the treatment of Demodex blepharitis.“This study hit all of the primary and secondary endpoints with very high statistical significance,” Azamian said. “The primary endpoint, to remind everyone, is a complete
Source: www.healio.comCategories: Latest Headlines, OphthalmologyTweet-
Bobak Azamian, MD, PhD, (@azamian) CEO and co-founder of @TarsusRx, discusses topline data from the Saturn-2 phase 3 study of TP-03 for the treatment of Demodex blepharitis. https://t.co/HcyQ5fDWop #blepharitis #mednews
-
-
Mashup Score: 2Beating the mighty Demodex mites - 2 year(s) ago
Demodex blepharitis is a virtual epidemic in the US; an estimated 20 million people have blepharitis, and of that population, almost half have Demodex. A new therapeutic is the sole treatment option that targets the disease.
Source: Ophthalmology TimesCategories: Latest Headlines, OphthalmologyTweet-
An estimated 20 million people in the US have #blepharitis, and of that population, almost half have #Demodex. A new #therapeutic is the sole treatment option that targets the disease. Learn more: https://t.co/IxW72OJOvX #Ophthalmology #clinical #ocular #cataract https://t.co/7bYOQC4AXy
-
-
Mashup Score: 4Beating the mighty Demodex mites - 2 year(s) ago
Demodex blepharitis is a virtual epidemic in the US; an estimated 20 million people have blepharitis, and of that population, almost half have Demodex. A new therapeutic is the sole treatment option that targets the disease.
Source: Ophthalmology TimesCategories: Latest Headlines, OphthalmologyTweet-
An estimated 20 million people in the US have #blepharitis, and of that population, almost half have #Demodex. A new #therapeutic is the sole treatment option that targets the disease. Learn more: https://t.co/f4hAg42zTi #Ophthalmology #clinical #ocular #cataract https://t.co/G51kSWdEV0
-
-
Mashup Score: 2Beating the mighty Demodex mites - 2 year(s) ago
Demodex blepharitis is a virtual epidemic in the US; an estimated 20 million people have blepharitis, and of that population, almost half have Demodex. A new therapeutic is the sole treatment option that targets the disease.
Source: Ophthalmology TimesCategories: Latest Headlines, OphthalmologyTweet-
An estimated 20 million people in the US have #blepharitis, and of that population, almost half have #Demodex. A new #therapeutic is the sole treatment option that targets the disease. https://t.co/pCc64ErPrx #Ophthalmology #clinical #ocular #cataract https://t.co/YSrHDFonE8
-
-
Mashup Score: 3Patient treatment complete in phase 2b blepharitis trial - 3 year(s) ago
The final patient has completed the treatment stage of a phase 2b clinical trial investigating NCX 4251 for blepharitis, according to a press release from Nicox. The Mississippi trial, which is investigating NCX 4251 0.1% (fluticasone propionate nanocrystals ophthalmic suspension), recruited more than 200 patients. The primary outcome measures include the proportion of patients on NCX 4251 vs.
Source: www.healio.comCategories: Latest Headlines, OphthalmologyTweet-
Patient treatment complete in phase 2b blepharitis trial https://t.co/LGNwmlYSSa #ophthalmology #blepharitis
-
-
Mashup Score: 3TP-03 for Demodex blepharitis meets endpoints in pivotal trial - 3 year(s) ago
TP-03 met all primary and secondary endpoints in a phase 2b/3 trial and had no serious treatment-related adverse events or discontinuations in the treatment of Demodex blepharitis, according to a press release from Tarsus Pharmaceuticals.The randomized, controlled, multicenter, double-masked pivotal Saturn-1 trial investigated the safety and efficacy of TP-03 (lotilaner ophthalmic solution 0.25%)
Source: www.healio.comCategories: Latest Headlines, OphthalmologyTweet-
TP-03 for Demodex blepharitis meets endpoints in pivotal trial https://t.co/Fx3VGRauMv #blepharitis #ophthalmology
-
An estimated 20 million people in the US have #blepharitis, and of that population, almost half have #Demodex. A new #therapeutic is the sole treatment option that targets the disease. Learn more: https://t.co/tU7CrsaJt1 #Ophthalmology #clinical #ocular #cataract https://t.co/VA6tyjhCXU